Company Expects to Report its Fiscal Fourth Quarter and
                 2004 Year-End Results On September 28, 2004

    WAYNE, Pa., Sept. 24 /PRNewswire-FirstCall/ -- Escalon Medical Corp.
(Nasdaq Small Cap: ESMC) announced that to date, Escalon has received
acceptances from the holders of approximately 93.7% of the issued ordinary
shares outstanding of Drew Scientific Group PLC, for which Escalon has or will
issue approximately 843,000 shares of Escalon common stock of the 900,000
shares offered pursuant to the exchange offer.  With the expiration of the
latest extension, its revised purchase offer is now closed.  Escalon now
intends to use the procedures established under United Kingdom law to
compulsorily acquire any remaining Drew Shares.
    As of September 8, 2004, the ordinary shares of Drew Scientific have been
delisted with the United Kingdom Listing Authority, and trading with the
London Stock Exchange Plc has been cancelled.
    Escalon also announced that it expects to report its fiscal fourth quarter
and 2004 year end results for the period ending June 30, 2004 on September 28,
2004.

    Drew Scientific, based in the U.K., with additional manufacturing
operations in Texas and Connecticut, is a diagnostics company specializing in
the design, manufacture, sale and distribution of analytical systems for
laboratory testing worldwide.  Drew Scientific provides instrumentation and
consumables for the diagnosis and monitoring of medical disorders in the areas
of diabetes, cardiovascular diseases and hematology, as well as veterinary
hematology and blood chemistry.

    Founded in 1987, Escalon develops, markets and distributes ophthalmic
diagnostic, surgical and pharmaceutical products as well as vascular access
devices.  Escalon seeks to further diversify its product line to achieve
critical mass in sales and take better advantage of Escalon's distribution
capabilities through internal product development, acquisitions or strategic
partnerships.  Escalon has headquarters in Wayne, Pennsylvania and
manufacturing operations in Long Island, New York and New Berlin, Wisconsin.

    Note:  This press release contains statements that are considered forward-
looking under the Private Securities Litigation Reform Act of 1995, including
statements about Escalon's future prospects.  They are based on Escalon's
current expectations and are subject to a number of uncertainties and risks,
and actual results may differ materially.  The uncertainties and risks include
whether Escalon is able to improve upon the operations of Escalon's business
units, generate cash and identify, finance and enter into business
relationships and acquisitions, uncertainties and risks related to new product
development, commercialization, manufacturing and market acceptance of new
products, marketing acceptance of existing products in new markets, research
and development activities, including failure to demonstrate clinical
efficacy, delays by regulatory authorities, scientific and technical advances
by Escalon or third parties, introduction of competitive products, third party
reimbursement and physician training as well as general economic conditions.
Further information about these and other relevant risks and uncertainties may
be found in Escalon's report on Form 10-K, and its other filings with the
Securities and Exchange Commission, all of which are available from the
Commission as well as other sources.

Link to this page: